Physician profile
Preeth A Menon
NPI 1598729386
$3,444.01
in general payments reported to CMS, 2019-2025
36 companies · $78.63 in 2025
The $78.63 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $603 · 2021: $1,321 · 2022: $288 · 2023: $383 · 2024: $419 · 2025: $78.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $566.56 | 2021-2025 | |
| Forte Bio-Pharma LLC | $337.64 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $299.89 | 2021 | |
| Eisai INC. | $211.91 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $206.17 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $157.68 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $153.65 | 2023-2024 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $146.33 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $137.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $130.94 | 2020-2022 | |
| Lilly USA, LLC | $113.42 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Indivior INC. | $110.53 | 2020-2024 | Sublocade |
| Amgen INC. | $79.58 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.96 | 2022 | |
| Arbor Pharmaceuticals, INC. | $71.43 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $66.96 | 2020-2021 | |
| Biotronik INC. | $65.30 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.35 | 2025 | Caplyta |
| Uswm, LLC | $47.36 | 2023 | Lucemyra |
| Braeburn INC. | $41.31 | 2023-2024 | Brixadi |
| Alkermes, INC. | $38.67 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.30 | 2019 | |
| Lundbeck LLC | $36.74 | 2020-2023 | Vyepti |
| Hospira, INC. | $35.59 | 2021 | |
| Alnylam Pharmaceuticals INC. | $27.58 | 2021 | |
| Avanir Pharmaceuticals, INC. | $24.23 | 2020 | |
| Genzyme Corporation | $24.20 | 2021 | |
| Pfizer INC. | $21.48 | 2024 | |
| Nevro Corp. | $18.49 | 2024 | Senza |
| Sunovion Pharmaceuticals INC. | $17.43 | 2019 | |
| Neurelis, INC. | $16.46 | 2021 | |
| Dynasplint Systems INC. | $14.56 | 2023 | Dynasplint |
| Allergan, INC. | $14.06 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.34 | 2020 | |
| Currax Pharmaceuticals LLC | $12.13 | 2020 | |
| Kaleo, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preeth Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.